Skip to main content

David Strack, Jeffrey Williams, Neal Harte, Christopher Dick, Peter Johnson, Mark Braughler, Douglas Morton, Donald Steen, Paul Queally, Brian Beatty, Anthony Recupero, Dennis Langer


David Strack has been promoted to president of Genomic Solutions following the departure of Jeffrey Williams to become CEO at another company, parent company Harvard Bioscience said last week.

Before his promotion, Strack was vice president of sales and marketing at Genomic Solutions and will remain president of HBIO’s subsidiary Union Biometrica.

Genomic Solutions has also appointed Neal Harte to its board, replacing Christopher Dick, who resigned. Neal was previously executive vice president and vice chairman of Vitale, Caturano and Company.

Paradigm Genetics has hired Peter Johnson as executive vice president and chief medical officer, and Mark Braughler as vice president for business development in healthcare. The moves follow Paradigm’s acquisition of TissueInformatics.

Johnson was chairman and CEO of TissueInformatics. He holds an MD from the State University of New York Upstate Medical Center and a BS from the University of Notre Dame.

Braughler was senior vice president for business development of TissueInformatics. He holds a PhD in pharmacology from the University of Pittsburgh School of Medicine.

In addition, Douglas Morton has joined Paradigm’s board of directors. He is the CEO of the Southwest Michigan Innovation Center, and was a vice president at Pfizer until last year. Morton holds an AB in chemistry from Kenyon College and a PhD in organic chemistry from Columbia University.

AmeriPath has appointed Donald Steen to its board of directors. He will also serve as the board’s chairman; Paul Queally, the current chairman, was elected as chairman of the executive committee.

GeneEd has appointed Brian Beatty to its scientific/educational advisory board. Beatty is an assistant professor in the instructional technology department at San Francisco State University.

Beatty comes to GeneEd from Indiana University, where he was project manager for the “Learning to Teach with Technology Studio program.” He received his PhD in Instructional systems technology from Indiana University Bloomington and holds an MA in instructional technologies from San Francisco State University and a BS in electrical engineering from Marquette University.

Anthony Recupero has joined MaxCyte as vice president for business development, the Rockville, Md.-based company said this week. He is the former senior director for business development at Gene Logic. Recupero holds a PhD in molecular and cell biology from the University of Cincinnati.

Dennis Langer has been elected to the board of directors of Myriad Genetics, the company said this week. He is a clinical professor at the department of psychiatry at Georgetown University School of Medicine and the president for North America at Dr Reddy’s Laboratories.

Prior to that, he was senior vice president for project and portfolio management, research, and development at GlaxoSmithKline. Langer holds a JD from Harvard Law School and an MD from Georgetown University School of Medicine, as well as a BA in biology from Columbia University.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.